Silo Pharma, Inc.
SILO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001514183
No open-market purchases or sales by Silo Pharma, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q3 2026, worth $451.7K in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $4.05M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +4 vs. previous quarter
- 13
- 13F valueReported value at the end of Q3 2026
- $451.7K
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $72.1K
- 0.0% year over year
- Net income, FY2025
- -$4.23M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- −100.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $4.23M (5863.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 13.8K
- Shares sold short
- Change
- −8.29K
- −37.6% vs. previous
- Days to cover
- 1.07
- At average daily volume
Superinvestors holding SILO, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding SILO at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Silo Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 (view filing)6:34 PM ET | Dec 15 | 1 day | Weisblum EricChief Executive Officer | PPurchase | +5.00K | $0.415 | +$2.08K | +2.4%216.9K after | 2 lots |
| Nov 21, 2025 (view filing)6:35 PM ET | Nov 20-21 | 1 day | Weisblum EricChief Executive Officer | PPurchase | +2.00K | $0.3675 | +$735 | +1.0%211.9K after | 2 lots |
| Nov 20, 2025 (view filing)4:00 PM ET | Nov 18-19 | 2 days | Weisblum EricChief Executive Officer | PPurchase | +12.0K | $0.4039 | +$4.85K | +6.1%209.9K after | 2 lots |
| May 28, 2025 (view filing)4:30 PM ET | May 27 | 1 day | Weisblum EricChief Executive Officer | PPurchase | +10.0K | $0.4329 | +$4.33K | +5.3%197.9K after | |
| Dec 16, 2024 (view filing) | Dec 13 | 3 days | Weisblum EricCEO and President | PPurchase | +2.50K | $0.84 | +$2.10K | +1.3%187.9K after | |
| Nov 22, 2024 (view filing) | Nov 20-22 | 2 days | Weisblum EricCEO and President | PPurchase | +5.00K | $0.925 | +$4.63K | +2.8%185.4K after | 2 lots |
| Jun 13, 2024 (view filing) | Jun 11-12 | 2 days | Weisblum EricCEO and President | PPurchase | +5.00K | $1.11 | +$5.53K | +2.9%180.4K after | 2 lots |
| Apr 8, 2024 (view filing) | Apr 4-5 | 4 days | Weisblum EricCEO and President | PPurchase | +1.00K | $1.99 | +$1.99K | +0.6%175.4K after | 2 lots |
| Apr 1, 2024 (view filing) | Mar 28-Apr 1 | 4 days | Weisblum EricCEO and President | PPurchase | +4.51K | $1.93 | +$8.71K | +2.7%174.4K after | 2 lots |
| Dec 21, 2023 (view filing) | Dec 19-20 | 2 days | Weisblum EricCEO and President | PPurchase | +700 | $1.62 | +$1.14K | +0.4%169.9K after | 2 lots |
Top 10 13F holders, Q3 2026
See all 13 holdersThe largest institutional positions in Silo Pharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 103,983 | $157.0K | 0.02% | +103,983 | New |
| AdvisorShares Investments LLC | 103,472 | $156.2K | 0.02% | +27,890+36.9% | Added |
| Renaissance Technologies LLC | 23,500 | $35.5K | 0.00% | +23,500 | New |
| Citadel Advisors LLC | 16,441 | $24.8K | 0.00% | −359−2.1% | Reduced |
| Vanguard Capital Management LLC | 11,956 | $18.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 11,515 | $17.4K | 0.00% | +11,515 | New |
| Geode Capital Management, LLC | 11,283 | $17.0K | 0.00% | +11,283 | New |
| Virtu Financial LLC | 10,459 | $16.0K | 0.00% | +10,459 | New |
| FNY Investment Advisers, LLC | 5,000 | $7.00K | 0.00% | −32,507−86.7% | Reduced |
| Vanguard Fiduciary Trust Co | 874 | $1.32K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of SILO
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Silo Pharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Intracoastal Capital, LLC | 13G/A | 9.99%1.48M shares | 0.00 ppfrom 9.99% | Jun 13, 20246 filings | Feb 13, 2026 | SEC |
| Intracoastal Capital, LLC | 13G/A | 9.99%176.2K shares | 0.00 ppfrom 9.99% | Aug 13, 20262 filings | Nov 10, 2026 | SEC |
| AdvisorShares Trust | 13G | 6.69%75.6K shares | New | Jul 8, 20261 filing | Jul 8, 2026 | SEC |
| Anson Funds Management LP | 13G | 6.60%104.0K shares | New | Nov 16, 20261 filing | Nov 16, 2026 | SEC |